67 related articles for article (PubMed ID: 25960241)
21. Lung cancer in HIV positive patients: the GICAT experience.
Bearz A; Vaccher E; Martellotta F; Spina M; Talamini R; Lleshi A; Cacopardo B; Nunnari G; Berretta M; Tirelli U;
Eur Rev Med Pharmacol Sci; 2014; 18(4):500-8. PubMed ID: 24610616
[TBL] [Abstract][Full Text] [Related]
22. Combined MUC1-specific nanobody-tagged PEG-polyethylenimine polyplex targeting and transcriptional targeting of tBid transgene for directed killing of MUC1 over-expressing tumour cells.
Sadeqzadeh E; Rahbarizadeh F; Ahmadvand D; Rasaee MJ; Parhamifar L; Moghimi SM
J Control Release; 2011 Nov; 156(1):85-91. PubMed ID: 21704663
[TBL] [Abstract][Full Text] [Related]
23. MUC1 expression is regulated by DNA methylation and histone H3 lysine 9 modification in cancer cells.
Yamada N; Nishida Y; Tsutsumida H; Hamada T; Goto M; Higashi M; Nomoto M; Yonezawa S
Cancer Res; 2008 Apr; 68(8):2708-16. PubMed ID: 18413738
[TBL] [Abstract][Full Text] [Related]
24. Expression of human full-length MUC1 inhibits the proliferation and migration of a B16 mouse melanoma cell line.
Wang F; Li Q; Ni W; Fang F; Sun X; Xie F; Wang J; Wang F; Gao S; Tai G
Oncol Rep; 2013 Jul; 30(1):260-8. PubMed ID: 23633115
[TBL] [Abstract][Full Text] [Related]
25. The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens.
Maggiolo F; Ripamonti D; Torti C; Arici C; Antinori A; Quiros-Roldan E; Minoli L; Sighinolfi L; Nasta P; Suter F;
Antivir Ther; 2006; 11(7):923-9. PubMed ID: 17302255
[TBL] [Abstract][Full Text] [Related]
26. Nrf2 knockdown by shRNA inhibits tumor growth and increases efficacy of chemotherapy in cervical cancer.
Ma X; Zhang J; Liu S; Huang Y; Chen B; Wang D
Cancer Chemother Pharmacol; 2012 Feb; 69(2):485-94. PubMed ID: 21842204
[TBL] [Abstract][Full Text] [Related]
27. In vivo radioiodide imaging and treatment of pancreatic cancer xenografts after MUC1 promoter-driven expression of the human sodium-iodide symporter.
Chen RF; Li ZH; Pan QH; Zhou JJ; Tang QB; Yu FY; Zhou QB; Wang J; Chen JS
Pancreatology; 2007; 7(5-6):505-13. PubMed ID: 17912014
[TBL] [Abstract][Full Text] [Related]
28. Hypoxia enhances MUC1 expression in a lung adenocarcinoma cell line.
Mikami Y; Hisatsune A; Tashiro T; Isohama Y; Katsuki H
Biochem Biophys Res Commun; 2009 Feb; 379(4):1060-5. PubMed ID: 19141292
[TBL] [Abstract][Full Text] [Related]
29. In vivo effects of highly active antiretroviral therapies containing the protease inhibitor nelfinavir on mitochondrially driven apoptosis.
Miró O; Villarroya J; Garrabou G; López S; Rodríguez de la Concepción M; Pedrol E; Martínez E; Giralt M; Gatell JM; Cardellach F; Casademont J; Villarroya F
Antivir Ther; 2005; 10(8):945-51. PubMed ID: 16430200
[TBL] [Abstract][Full Text] [Related]
30. AIDS malignancies in the era of highly active antiretroviral therapy.
Gates AE; Kaplan LD
Oncology (Williston Park); 2002 Apr; 16(4):441-51, 456, 459. PubMed ID: 12017534
[TBL] [Abstract][Full Text] [Related]
31. [Highly Active AntiRetroviral Therapy and cryptosporidiosis].
Morales Gomez MA
Parassitologia; 2004 Jun; 46(1-2):95-9. PubMed ID: 15305695
[TBL] [Abstract][Full Text] [Related]
32. [Epidemiology of HIV-associated malignancies].
Launay O; Guillevin L
Bull Cancer; 2003 May; 90(5):387-92. PubMed ID: 12850760
[TBL] [Abstract][Full Text] [Related]
33. MUC1 gene overexpressed in breast cancer: structure and transcriptional activity of the MUC1 promoter and role of estrogen receptor alpha (ERalpha) in regulation of the MUC1 gene expression.
Zaretsky JZ; Barnea I; Aylon Y; Gorivodsky M; Wreschner DH; Keydar I
Mol Cancer; 2006 Nov; 5():57. PubMed ID: 17083744
[TBL] [Abstract][Full Text] [Related]
34. Superior virological response to boosted protease inhibitor-based highly active antiretroviral therapy in an observational treatment programme.
Wood E; Hogg RS; Yip B; Moore D; Harrigan PR; Montaner JS
HIV Med; 2007 Mar; 8(2):80-5. PubMed ID: 17352763
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic approaches to AIDS-related malignancies.
Berretta M; Cinelli R; Martellotta F; Spina M; Vaccher E; Tirelli U
Oncogene; 2003 Sep; 22(42):6646-59. PubMed ID: 14528290
[TBL] [Abstract][Full Text] [Related]
36. Review of screening guidelines for non-AIDS-defining malignancies: evolving issues in the era of highly active antiretroviral therapy.
Tyerman Z; Aboulafia DM
AIDS Rev; 2012; 14(1):3-16. PubMed ID: 22297500
[TBL] [Abstract][Full Text] [Related]
37. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic.
Ives NJ; Gazzard BG; Easterbrook PJ
J Infect; 2001 Feb; 42(2):134-9. PubMed ID: 11531320
[TBL] [Abstract][Full Text] [Related]
38. [Efficacy of anti-HIV treatment and drug-resistance mutations in some parts of China].
Han XX; Zhang M; Cui WG; Liu BG; Wang Yn; Zhang ZN; Liu J; Geng WQ; Diao YY; Dai D; Jiang YJ; Shang H
Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(11):760-4. PubMed ID: 15949383
[TBL] [Abstract][Full Text] [Related]
39.
Ndlovu SS; Chuturgoon AA; Ghazi T
Plants (Basel); 2023 Apr; 12(7):. PubMed ID: 37050167
[TBL] [Abstract][Full Text] [Related]
40.
Sibiya T; Ghazi T; Mohan J; Nagiah S; Chuturgoon AA
Plants (Basel); 2022 Dec; 12(1):. PubMed ID: 36616248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
